ImmuPharma plc (LON:IMM – Get Free Report) shares fell 10.5% on Tuesday . The company traded as low as GBX 2.60 ($0.03) and last traded at GBX 2.82 ($0.03). 2,858,942 shares changed hands during trading, a decline of 86% from the average session volume of 20,779,262 shares. The stock had previously closed at GBX 3.15 ($0.04).
ImmuPharma Stock Performance
The company has a market cap of £11.74 million, a P/E ratio of -282.00 and a beta of 1.53. The firm’s fifty day moving average is GBX 1.62 and its two-hundred day moving average is GBX 1.69.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- What is a Bond Market Holiday? How to Invest and Trade
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- 5 Top Rated Dividend Stocks to Consider
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
